Sunitinib, hypertension, and heart failure: A model for kinase inhibitor-mediated cardiotoxicity

Current Hypertension Reports

Volumn 13, Issue 6, 2011, Pages 430-435

  Gupta, Rajesh ^b   Maitland, Michael L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiomyopathy; Heart failure; Hypertension; Kinase inhibitor; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMATINIB; PACLITAXEL; PAZOPANIB; PILOCARPINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR; VERAPAMIL;

ACUTE CORONARY SYNDROME; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); MOLECULAR MECHANICS; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; HYPERTENSION; INDOLES; MYOCYTES, CARDIAC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; RISK FACTORS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81255184828     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0229-4     Document Type: Article

References (32)

1. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma New Engl J Med 356 2 115 124 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
2. GD Demetri AT van Oosterom CR Garrett, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 1329 1338 17046465 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL (Pubitemid 44528723)
3. E Raymond L Dahan JL Raoul, et al. 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors New Engl J Med 364 6 501 513 21306237 10.1056/NEJMoa1003825 1:CAS:528:DC%2BC3MXhvVyisrY%3D
4. TF Chu MA Rupnick R Kerkela, et al. 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 9604 2011 2019 18083403 10.1016/S0140-6736(07)61865-0 1:CAS:528:DC%2BD2sXhsVent7bN (Pubitemid 350236338)
5. V Chintalgattu SS Patel AY Khakoo 2009 Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors Hematol Oncol Clin North Am 23 1 97 107 19248973 10.1016/j.hoc.2008.11.004 viii-ix
6. J Zhang PL Yang NS Gray 2009 Targeting cancer with small molecule kinase inhibitors Nat Rev Canc 9 1 28 39 10.1038/nrc2559
7. H Cheng T Force 2010 Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics Circ Res 106 1 21 34 20056943 10.1161/CIRCRESAHA. 109.206920 1:CAS:528:DC%2BD1MXhs1aqt7nI
8. T Force KL Kolaja 2011 Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat Rev Drug Discov 10 2 111 126 21283106 10.1038/nrd3252 1:CAS:528:DC%2BC3MXhtlektrg%3D
9. ML Rees AY Khakoo 2011 Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies Heart Fail Clin 7 3 299 311 21749882 10.1016/j.hfc.2011.03.004
10. X Zhu K Stergiopoulos S Wu 2009 Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 1 9 17 18752081 10.1080/02841860802314720 1:CAS:528:DC%2BD1cXhsFagtbjI
11. BI Rini DP Cohen DR Lu, et al. 2011 Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Canc Inst 103 9 763 773 10.1093/jnci/djr128 1:CAS:528: DC%2BC3MXlvVOqtLc%3D
12. ML Maitland KE Kasza T Karrison, et al. 2009 Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment Clin Canc Res 15 19 6250 6257 10.1158/1078-0432.CCR-09-0058 1:CAS:528:DC%2BD1MXhtF2lurjJ
13. M Azizi A Chedid S Oudard 2008 Home blood-pressure monitoring in patients receiving sunitinib New Engl J Med 358 1 95 97 18172185 10.1056/NEJMc072330 1:CAS:528:DC%2BD1cXisFaiuw%3D%3D This study demonstrated the potential for blood pressure as a pharmacodynamic marker of sunitinib. It was the first study to clearly demonstrate the return of blood pressure to baseline levels with sunitinib withdrawal
14. CS Facemire AB Nixon R Griffiths, et al. 2009 Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression Hypertension 54 3 652 658 19652084 10.1161/HYPERTENSIONAHA.109.129973 1:CAS:528:DC%2BD1MXpslektL4%3D
15. ES Robinson EV Khankin TK Choueiri, et al. 2010 Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors Hypertension 56 6 1131 1136 20956731 10.1161/HYPERTENSIONAHA.110.160481 1:CAS:528:DC%2BC3cXhsVCrsLrJ
16. JJ Mourad G des Guetz H Debbabi BI Levy 2008 Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation Ann Oncol 19 5 927 934 18056916 10.1093/annonc/mdm550 This study demonstrated that capillary rarefaction occurs in human patients after prolonged treatment with a regimen containing bevacizumab (Pubitemid 351627309)
17. T Kamba BY Tam H Hashizume, et al. 2006 VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart Circ Physiol 290 2 H560 H576 16172168 10.1152/ajpheart.00133.2005 1:CAS:528:DC%2BD28XhsFKjuro%3D
18. M Schmidinger CC Zielinski UM Vogl, et al. 2008 Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 32 5204 5212 18838713 10.1200/JCO.2007.15.6331
19. TK Choueiri EL Mayer Y Je, et al. 2011 Congestive heart failure risk in patients with breast cancer treated with bevacizumab J Clin Oncol 29 6 632 638 21205755 10.1200/JCO.2010.31.9129 1:CAS:528:DC%2BC3MXjvVSku7g%3D
20. HL McArthur H Rugo B Nulsen, et al. 2011 A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer Clin Canc Res 17 10 3398 3407 10.1158/1078-0432.CCR-10-1969 1:CAS:528:DC%2BC3MXmtVGit7k%3D
21. V Chintalgattu D Ai RR Langley, et al. 2010 Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress J Clin Investig 120 2 472 484 20071776 10.1172/JCI39434 1:CAS:528:DC%2BC3cXhsVOktL8%3D This mechanistic study demonstrated the importance of PDGF signaling in cardiac response to afterload stress and forms the basis for the "two-hit" hypothesis of KI-associated cardiac toxicity
22. MW Karaman S Herrgard DK Treiber, et al. 2008 A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 1 127 132 18183025 10.1038/nbt1358 1:CAS:528:DC%2BD1cXisFGlsQ%3D%3D
23. K Ghoreschi A Laurence JJ O'Shea 2009 Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 10 4 356 360 19295632 10.1038/ni.1701 1:CAS:528:DC%2BD1MXjtlyms78%3D
24. R Kerkela KC Woulfe JB Durand, et al. 2009 Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase Clin Transl Sci 2 1 15 25 20376335 10.1111/j.1752-8062.2008.00090.x 1:CAS:528:DC%2BD1MXntlemtrY%3D
25. ML Maitland GL Bakris HR Black, et al. 2010 Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Canc Inst 102 9 596 604 10.1093/jnci/djq091 1:CAS:528:DC%2BC3cXlvVWqtr0%3D This article provides a more comprehensive rationale for blood pressure control in patients receiving VEGF signaling pathway inhibitors
26. MH Langenberg CM van Herpen J De Bono, et al. 2009 Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors J Clin Oncol 27 36 6152 6159 19901116 10.1200/JCO.2009.22.2273 1:CAS:528: DC%2BC3cXht1agsb8%3D
27. SE Dahlberg AB Sandler JR Brahmer, et al. 2010 Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol 28 6 949 954 20085937 10.1200/JCO.2009.25.4482 1:CAS:528:DC%2BC3cXktF2ltr8%3D Many prior publications reported an association between hypertension and therapeutic effects of VEGF signaling inhibitors. This analysis relied on intravenously administered bevacizumab and an optimal "landmark analysis" interrogation and should be recognized as the first to demonstrate convincingly an association between blood pressure elevations and improved outcomes with this class of anticancer agents
28. JO Curwen HL Musgrove J Kendrew, et al. 2008 Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy Clin Canc Res 14 10 3124 3131 10.1158/1078-0432.CCR-07-4783 1:CAS:528:DC%2BD1cXmtVCmurw%3D
29. PH Franklin PN Banfor P Tapang, et al. 2009 Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl) phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition J Pharmacol Exp Ther 329 3 928 937 19255283 10.1124/jpet.108.144816 1:CAS:528:DC%2BD1MXms1ehur0%3D
30. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma New Engl J Med 356 2 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
31. CN Sternberg ID Davis J Mardiak, et al. 2010 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 6 1061 1068 20100962 10.1200/JCO.2009.23.9764 1:CAS:528:DC%2BC3cXktF2lt78%3D
32. AM Arnold L Seymour M Smylie, et al. 2007 Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR$20 J Clin Oncol 25 27 4278 4284 17878480 10.1200/JCO.2007.12.3083 1:CAS:528:DC%2BD2sXhtFyis7jO (Pubitemid 47548568)